Hedera Dx
About Us
Hedera Dx is dedicated to transforming oncology by providing cutting-edge liquid biopsy solutions that improve patient experiences, outcomes and journeys, as well as healthcare professional experiences, while facilitating the prescription, discovery and development of the next breakthrough precision oncology therapies.
Our Vision and Mission
Hedera Dx was born to transform oncology globally by enabling routine use of validated liquid biopsies in-house, without compliance, bioinformatics and reporting hurdles at all stages of the disease.
By adopting both a customer- and a patient-centric approach in all activities and developments, systematically integrating Patient-Reported Outcomes (PROs), Patient-Reported Experience Measures (PREMs), patient groups and customer feedback, Hedera Dx ensures delivery of products and services that meet the needs of those who need it most.
By adopting both a customer- and a patient-centric approach in all activities and developments, systematically integrating Patient-Reported Outcomes (PROs), Patient-Reported Experience Measures (PREMs), patient groups and customer feedback, Hedera Dx ensures delivery of products and services that meet the needs of those who need it most.
Unique Customer Experience and Team
Hedera Dx partners with laboratories and clinicians to offer fast, locally CE-IVDR compliant, clinically actionable NGS-based liquid biopsy solutions processed in-house. The team is passionate about making liquid biopsies a standard practice worldwide to help cancer patients get better outcomes using a simple blood draw. The company was established in Switzerland in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, supported by leading investors.
